BioSpace News Archive

Trillium Health Partners (THP) and Trillium Health Partners Foundation (THPF) are honoured to announce an historic $105 million donation.

ImmunoGen Grants Lilly Exclusive Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Lilly with ImmunoGen’s Novel Camptothecin Platform.

NanoViricides, Inc has filed the quarterly report for second quarter of its 2022 fiscal year with the Securities and Exchange Commission.

Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, announced the establishment of a wholly owned subsidiary located in Tokyo, Japan to commercialize Palette’s portfolio of medical products.

Ipsen announced two-year follow-up results from analyses of the Phase III CheckMate -9ER trial, which demonstrated sustained survival and response rate benefits 1, as well as health-related quality of life improvements 2, with the combination of Cabometyx® and Opdivo® versus sunitinib in the first-line treatment of advanced renal cell carcinoma.

GENinCode Plc announces the successful completion of its NHS clinical study and positive results for its Lipid inCode® test for hypercholesterolemia, including Familial Hypercholesterolemia, undertaken at Royal Brompton and Harefield Hospitals, recently merged with Guy’s and St Thomas’ NHS Foundation Trust the largest specialist heart and lung centre in the UK.

OKYO Pharma Limited, a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announced the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration regarding the development plans for OK-101 to treat dry eye disease.

Medivir’s drug development focuses on a very promising and proprietary clinical project, fostroxacitabine bralpamide, with a clear therapeutic target, where the unmet medical needs remain extremely large, despite recent clinical advances

Calliditas Therapeutics AB announced that the first patient has been randomized in the company’s pivotal phase 2b/3 TRANSFORM study in patients with primary biliary cholangitis.

Cerevel Therapeutics today announced positive results from its Phase 1 healthy volunteer clinical trial to evaluate darigabat, a novel alpha-2/3/5 selective GABAA receptor positive allosteric modulator (PAM), in acute anxiety.